리라나프테이트
리라나프테이트 · LNF · M-732 · ZEFNART · LIRANAFATE · LIANAFTATE · LIRANAFTATE · PIRITETRATE
식별자 및 물리적 특성
| CAS No. | 88678-31-3 |
|---|---|
| 분자식 | C18H20N2O2S |
| 평균 분자량 | 328.4 g/mol |
| 단동위원소 질량 | 328.12454906 g/mol |
| SMILES | COc1cccc(N(C)C(=S)Oc2ccc3c(c2)CCCC3)n1 |
| InChIKey | VPHPQNGOVQYUMG-UHFFFAOYSA-N |
| PubChem CID | 3936 |
| ChEMBL | CHEMBL1591365 |
| ChEBI | CHEBI:31775 |
| EC No. | 834-254-6 |
| DTXSID | DTXSID6046470 |
| 현지명 | 리라나프테이트 |
화학 및 물리적 성질
| XLogP | 4.9 |
|---|---|
| 극성 표면적 | 66.7 |
| 수소 결합 공여자 수 | 0 |
| 수소 결합 수용자 수 | 4 |
| 회전 가능 결합 수 | 4 |
| 무거운 원자 수 | 23 |
| 형식 전하 | 0 |
| 복잡도 | 406 |
| 녹는점 | 98.5-99.5°C |
| 끓는 점 | 462.5±55.0 °C(Predicted) |
| 밀도 | 1.240±0.06 g/cm3(Predicted) |
| 저장 조건 | Keep in dark place,Sealed in dry,Room Temperature |
| 용해도 | DMSO(약간 용해됨), 메탄올(약간 용해됨, 가열) |
| 물리적 상태 | 고체 |
| pKa(산도 계수) | 1.24±0.10(Predicted) |
| 색상 | 회백색 |
| Merck | 14,5515 |
| InChI | InChI=1S/C18H20N2O2S/c1-20(16-8-5-9-17(19-16)21-2)18(23)22-15-11-10-13-6-3-4-7-14(13)12-15/h5,8-12H,3-4,6-7H2,1-2H3 |
| InChIKey | VPHPQNGOVQYUMG-UHFFFAOYSA-N |
| SMILES | C(=S)(OC1=CC=C2C(=C1)CCCC2)N(C1=NC(OC)=CC=C1)C |
화학적 성질
White Crystalline Solid
안전 및 규제
| GHS 분류 | WarningH315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P272, P280, P302+P352, P305+P351+P338, P321, P332+P317, P333+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Skin Irrit. 2 (100%) |
| RTECS 번호 | FD3890000 |
| 관세 코드 | 2933.39.4100 |
용도
개요
Liranaftate was launched in Japan as a new topical antifungal for the treatment of dermatophycoses. This compound belonging to the thiocarbamate class of antifungals can be prepared by condensation of 5,6，7,8-tetrahydro-2-naphthol with the corresponding Npyridylthiocarbamoyl chloride. It is a potent and specific inhibitor of squalene epoxidase and consequently a blocker of ergosterol biosynthesis in fungi, without any detectable effect on mammalian cholesterol biosynthesis in rat liver at therapeutic dose levels. Liranaftate was found to be significantly more active than the other thiocarbamate tolnaftate against several dermatophytes, including Trichophyton mentagrophyfes, and against certain yeasts, such as Crypfococcus neoformans. On the other hand, it was inactive against a variety of Gram-positive and negative bacteria. When applicated as a 1 or 2% cream during clinical trials, it was well tolerated and no systemic absorption was observed.